학술논문
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
Document Type
Article
Author
Source
In: Human Vaccines and Immunotherapeutics . (Human Vaccines and Immunotherapeutics, 2023, 19(1))
Subject
Language
English
ISSN
2164554X
21645515
21645515